https://li01.tci-thaijo.org/index.php/JBAP/issue/feed 2026-02-16T23:13:27+07:00 Professor Dr. Kesara Na-Bangchang jbap@nu.ac.th Open Journal Systems <p><span style="font-size: medium;"><strong>Journal of Basic and Applied Pharmacology</strong> <strong>(J Basic App Pharmacol) </strong>(former title: Thai Journal of Pharmacology) is a peer-reviewed journal publishing original research articles, reviews, case reports, letters to editors and commentaries on pharmacology and related fields, i.e. pharmacodynamics, pharmacokinetics, pharmacotherapeutics, toxicology, clinical pharmacology, molecular pharmacology, pharmacogenetics/pharmacogenomics, comparative pharmacology, safety pharmacology, systems pharmacology, pharmacoepidemiology and ethnopharmacology. The research article and review of all fields must be peer-reviewed by at least three reviewers. Thai Journal of Pharmacology has been abstracted and indexed by <strong>Thai Journal Citation Index (TCI - Tier 1)</strong> and <strong>ASEAN Citation Index (ACI)</strong>. The indexing in the TCI and ACI is continued with the <strong>Journal of Basic and Applied Pharmacology.</strong></span><span style="font-size: medium;"><strong><br /></strong></span></p> <p> </p> <p><span style="font-size: medium;"><strong>ISSN: 2774-0854 (Online)</strong></span></p> https://li01.tci-thaijo.org/index.php/JBAP/article/view/269929 2025-11-23T12:44:18+07:00 Putu Ririn Andreani putu.a@kkumail.com Laddawan Senggunprai laddas@kku.ac.th Sarinya Kongpetch sarinyako@kku.ac.th Piman Pocasap pimapo@kku.ac.th Chavi Yenjai chayen@kku.ac.th Arthan Supakorn supakorn.a@snru.ac.th Auemduan Prawan peuamd@kku.ac.th

<p>Ovalitenin A, a chalcone extracted from the roots of <em>Millettia brandisiana</em> Kurz, has exhibited cytotoxic properties in various human cancer cells. However, the effects of this on cholangiocarcinoma (CCA), an aggressive malignancy of the bile duct epithelium, are still not well understood. This study investigated the anti-metastatic potential of ovalitenin A and its associated molecular mechanisms in CCA cells. Sulforhodamine B (SRB), wound-healing, and adhesion assays were used to test cell viability, migration, and adhesion, respectively. Western blotting was performed to quantify phosphorylated PI3K and VEGF proteins, and qRT-PCR was used to measure <em>MMP-9</em> and <em>TIMP-1 </em>mRNA. Ovalitenin A suppressed the proliferation of CCA cells in a concentration-dependent manner. Following 24 hours of treatment, it markedly diminished cell migration and adhesion. Network pharmacology analysis found 32 common targets between ovalitenin A and CCA utilizing the SwissTargetPrediction and GeneCards databases. Moreover, protein–protein interaction analysis revealed a robust association among these targets, indicating the involvement of PI3K-related signaling pathways. PIK3CA and MMP-family proteins were prioritized as candidate targets based on their centrality within the network and their well-established roles in CCA progression, metastasis, and extracellular matrix remodeling. As predicted, treatment of ovalitenin A reduced the levels of phosphorylated PI3K and VEGF proteins and lowered the ratio of <em>MMP-9</em> to <em>TIMP-1</em> mRNA. These findings suggest that ovalitenin A may reduce CCA metastasis, possibly by altering PI3K signaling and its downstream molecular effectors.</p>

2026-02-16T00:00:00+07:00 Copyright (c) 2026 Journal of Basic and Applied Pharmacology